Shares of EyePoint (EYPT) plunged on Monday, undermining the lower bound of a cup base, after its treatment for eye diseases missed the mark in a late-stage study. The company tested its drug, Duravyu, in patients with wet age-related macular degeneration. Although it reduced treatment burden by 42% and 56% of patients were supplement-free at week 56, the primary goal of… Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
